Valion Bio, Inc. (VBIO)

Every figure this model derived for VBIO, the value it took, and the element in the company's own XBRL it was read from — so any of it can be checked against the filing rather than taken on trust. As at 2025-09-30.

The figures, and where each came from

This is the part no other screener shows. Each figure below names the XBRL element it was read from, so it can be checked against the filing itself.

FigureValueXBRL tagAs at
capex 99,000 PaymentsToAcquirePropertyPlantAndEquipment 2026-06-30
cash 2,108,000 CashAndCashEquivalentsAtCarryingValue 2026-06-30
current assets 3,382,000 AssetsCurrent 2026-06-30
current liabilities 3,046,000 LiabilitiesCurrent 2026-06-30
equity 4,246,000 StockholdersEquity 2026-06-30
interest expense 146,000 InterestExpenseNonoperating 2025-12-31
ocf -14,575,000 NetCashProvidedByUsedInOperatingActivities 2026-06-30
revenue 302,000 RevenueFromContractWithCustomerExcludingAssessedTax 2025-09-30
sbc 629,000 ShareBasedCompensation 2026-06-30

The ratios

The figures themselves rather than their scores — what somebody looking up VBIO on one particular measure came for.

RatioValue
current ratio1.11
current ratio reported1.11
deferred revenue growth-100.0
interest cover-113.12
revenue growth-49.67
revenue growth per share-49.67
rule of 40-5518.54
sbc pct revenue208.28

What to be careful about

What this model itself distrusts about VBIO's figures. Written by the derivation as it ran, not added afterwards.